Arecor Therapeutics (LON:AREC – Get Free Report) posted its quarterly earnings data on Thursday. The company reported GBX (8) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%.
Arecor Therapeutics Stock Up 3.4%
AREC stock traded up GBX 2.50 on Thursday, reaching GBX 75. 69,479 shares of the company traded hands, compared to its average volume of 24,878. Arecor Therapeutics has a one year low of GBX 56 and a one year high of GBX 95. The company has a market cap of £28.32 million, a P/E ratio of 37.50 and a beta of -0.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 4.35 and a quick ratio of 6.24. The firm has a fifty day simple moving average of GBX 71.57 and a 200-day simple moving average of GBX 67.96.
About Arecor Therapeutics
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Further Reading
- Five stocks we like better than Arecor Therapeutics
- Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
- Microsoft’s AI Spending Didn’t Change—Wall Street’s View of It Did
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
